GYRE vs ARIS Comparison

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Aris Water Solutions Inc is an environmental infrastructure and solutions company delivering full-cycle water handling and recycling solutions. Its integrated pipelines and related infrastructure create long-term value by delivering high-capacity, comprehensive produced water management, recycling, and supply solutions to operators in the core areas of the Permian Basin. The company manages its business through a single operating segment comprising two primary revenue streams, Produced Water Handling and Water Solutions. The Produced Water Handling business gathers, transports, and unless recycled, handles produced water generated from oil and natural gas production, and the Water Solutions business develops and operates recycling facilities to treat, store, and recycle produced water.